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for RTS,S are significantly more consistent and 
encouraging than the data available for SPf66 at 
any stage of its development. The comparison may 
not be informative. Nevertheless, we agree with 
Gosling and Chandramohan that point estimates 
of vaccine efficacy from phase 2b studies, such as 
the results we report, are surrounded by uncertain-
ty. RTS,S/AS01E will be evaluated in a wide range 
of transmission sites and over longer periods of 
follow-up in a planned phase 3 multicenter effi-
cacy trial.
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Antimalarial	Therapies	in	Children	from	Papua	New	Guinea
To the Editor: In their article on antimalarial 
combination therapies, Karunajeewa et al. (Dec. 11 
issue)1 conclude that artemether–lumefantrine has 
more favorable efficacy than dihydroartemisinin–
piperaquine, even though fat was given with the 
treatment only in the artemether–lumefantrine 
group and there was no significant difference in 
the primary end point. Their per-protocol analy-
sis with a high dropout rate from a small sample 
results in overestimation of the risk of treatment 
failure and wide 95% confidence intervals (6.4% 
to 20.0%). We reanalyzed data from 981 children 
younger than 5 years of age who were treated with 
dihydroartemisinin–piperaquine in seven clinical 
trials in Indonesia, Thailand, Uganda, and Burkina 
Faso. Dihydroartemisinin–piperaquine was admin-
istered with milk or a biscuit. Overall, the recru-
descence rate at day 42 was 3.1% (95% confidence 
interval, 1.9 to 4.3), ranging from 0 to 7.1%. The 
risk of recurrent malaria was significantly reduced 
after treatment with dihydroartemisinin–piper-
aquine as compared with artemether–lumefan-
trine (odds ratio, 0.51; P<0.001). 
Dihydroartemisinin–piperaquine is a highly 
effective treatment for multidrug-resistant falci-
parum malaria in young children and provides 
clinically significant post-treatment prophylaxis.2-4 
We recommend that both dihydroartemisinin–
piperaquine and artemether–lumefantrine be giv-
en with fat (milk, biscuit, or other food) to increase 
bioavailability.5
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The authors reply: Enhanced piperaquine bio-
availability with fat coadministration1 was re-
ported after our trial had started. There were no 
food-specific dosing recommendations for dihy-
droartemisinin–piperaquine then or subsequent-
ly.2 Other studies have shown excellent efficacy 
when fat coadministration was not required, and 
no pharmacokinetic factors, including baseline 
parasitemia, were independent determinants of 
the efficacy of dihydroartemisinin–piperaquine in 
our trial. Nevertheless, because low plasma piper-
aquine concentrations at day 7 predict recrudes-
cence3 and relevant bioavailability data are from 
healthy adults,1 pharmacokinetic studies (includ-
ing tolerability and safety) determining optimal 
fat intake in children with falciparum malaria 
would be valuable. We provided the justification 
for our sample size, analyzed and interpreted ef-
ficacy using current World Health Organization 
(WHO) guidelines,4 and presented best-case and 
worst-case scenarios for the effect of attrition on 
treatment outcome (see the Supplementary Appen-
dix, available with the full text of the article at 
NEJM.org). The lower 95% confidence limit for 
treatment failure with dihydroartemisinin–piper-
aquine at day 42 in per-protocol analyses (6.4%) 
was above the limit (<5%) recommended by the 
WHO for adoption of new therapy.4 The discor-
dance between this finding and low failure rates 
in other countries is likely to reflect the epidemio-
logic complexity of malaria and underscores the 
need for valid local efficacy trials before new treat-
ments are deployed.
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Smoking	Exposure,	17q21	Variants,	and	Early-Onset	Asthma
To the Editor: Bouzigon et al. (Nov. 6 issue)1 
report that single-nucleotide polymorphisms (SNPs) 
in the 17q21 region are associated with early-
onset asthma in subjects exposed to environmen-
tal tobacco smoke. One would predict that envi-
ronmental factors would have a greater effect in 
late-onset disease than in early-onset disease. We 
wonder whether the authors can provide data on 
SNPs that regulate susceptibility to late-onset 
asthma when there is passive exposure to tobac-
co smoke or when the subject is a smoker.
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The Authors Reply: We have shown that the 
risk of asthma conferred by genetic variants in 
chromosome 17q21 is restricted to early-onset 
asthma and is increased when there is exposure 
to environmental tobacco smoke in early life. Al-
though we found no association between 17q21 
variants and late-onset asthma, we further exam-
ined whether the relationship between 17q21 vari-
ants and late-onset asthma could be influenced 
by exposure to environmental tobacco smoke. There 
were 186 families in which all offspring (with or 
without late-onset asthma) had exposure to tobacco 
smoke in early life and 127 families in which all 
offspring did not have such exposure. We found 
no association between any of the variants previ-
ously investigated and late-onset asthma in ex-
posed or unexposed sibships (Table 1).1 We con-
clude that the interaction between the 17q21 locus 
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